23008-68-6

Usage

Uses

Used in Pharmaceutical and Agrochemical Synthesis:
2-(1,2-benzoxazol-3-yl)acetamide is used as a key intermediate in the synthesis of various pharmaceuticals and agrochemicals. Its versatile chemical properties allow for the development of new drugs and pesticides with improved efficacy and safety.
Used in Fluorescent Probes and Optical Brighteners:
BZA is utilized as a building block in the creation of fluorescent probes and optical brighteners. Its ability to emit light upon excitation makes it suitable for applications in bioimaging, diagnostics, and materials science.
Used in Neurodegenerative Disorder Treatment:
2-(1,2-benzoxazol-3-yl)acetamide has potential therapeutic applications in the treatment of neurodegenerative disorders. Its unique molecular structure may offer new avenues for the development of drugs targeting these debilitating conditions.
Used in Cancer Treatment:
BZA is being studied for its potential use in cancer treatment. Its ability to interact with biological targets and modulate cellular processes may contribute to the development of novel anticancer therapies.
Used in Environmental Toxicity Research:
2-(1,2-benzoxazol-3-yl)acetamide has been studied for its potential environmental toxicity and impact on aquatic organisms. Understanding its ecological effects is crucial for responsible development and use in various industries.

Upstream product

• 59899-89-7 1,2-benzisoxazol-3-ylacetic acid methyl ester 
• 4865-84-3 2-(benzo[d]isoxazol-3-yl)acetic acid 

Downstream Products

• 763026-39-7 3-(2-aminoethyl)-1,2-benzoisoxazole 
• 50471-14-2 N-(2-benzo[d]isoxazol-3-yl-acetimidoyl)-O-(3,4,5-trimethoxy-benzoyl)-hydroxylamine 
• 55985-59-6 N-(2-benzo[d]isoxazol-3-yl-acetimidoyl)-O-(3-phenyl-acryloyl)-hydroxylamine 
• 59899-85-3 (3-benzo[d]isoxazol-3-ylmethyl-[1,2,4]thiadiazol-5-yl)-phenyl-amine 
• 50471-13-1 2-benzo[d]isoxazol-3-yl-N-benzoyloxy-acetamidine 
• 59899-86-4 3-(5-phenyl-[1,2,4]oxadiazol-3-ylmethyl)-benzo[d]isoxazole 
• 59916-23-3 2-benzo[d]isoxazol-3-yl-N-hydroxy-N'-phenyl-acetamidine 

Relevant academic research and scientific papers

METHODS FOR HAIR FOLLICLE STEM CELL PROLIFERATION

The present invention relates to compositions of minoxidil and Sonic Hedgehog (Shh) pathway activators and optionally, Wnt agonists and methods of using them to induce self-renewal of hair follicle stem cells, including inducing the hair follicle stem cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into hair follicle epithelial cells.

1H-PYRROLE-2,5-DIONE COMPOUNDS AND METHODS OF USING THEM TO INDUCE SELF-RENEWAL OF STEM/PROGENITOR SUPPORTING CELLS

The present invention relates to 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells, including inducing the stem/progenitor cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into tissue cells.

METHODS FOR HAIR FOLLICLE STEM CELL PROLIFERATION

The present invention relates to compositions of Sonic Hedgehog (Shh) pathway activators and Wnt agonists and methods of using them to induce self-renewal of hair follicle stem cells, including inducing the hair follicle stem cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into hair follicle epithelial cells.

IDO inhibitors

Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.